100+ Free TEOC Oncologia Clínica Practice Questions

Prepare for the TEOC — Título de Especialista em Oncologia Clínica (Sociedade Brasileira de Oncologia Clínica / AMB) exam with instant access — no signup required.

✓ No registration✓ No credit card✓ No hidden fees✓ Start practicing immediately

100+ Questions

100% Free

Loading practice questions...

Same family resources

Explore More Brazilian Medical Association Specialty Title Concursos (AMB / Título de Especialista)

Continue into nearby exams from the same family. Each card keeps practice questions, study guides, flashcards, videos, and articles in one place.

CBR Prova de Título de Especialista em Radiologia e Diagnóstico por Imagem (Brazil)

Practice Questions100 questions

2026 Statistics

Key Facts: TEOC Oncologia Clínica Exam

100 Items

Four-option MCQs on the official TEOC Prova Teórica

Edital TEOC SBOC nº 2524/2026

2 Days

Virtual examination duration (Day 1: Prova Teórica; Day 2: Prova Teórico-Prática)

Edital TEOC SBOC nº 2524/2026

R$ 1.700,00

Registration Fee for SBOC/AMB Affiliated Members (R$ 2.700,00 for Non-Members)

Edital TEOC SBOC / AMB

70 Points

Minimum Final Passing Grade Benchmark (Cutoff 60 on Prova Teórica)

Edital TEOC SBOC / AMB

RQE Oncologia Clínica

Specialist Registration Credential Conferred with CFM

Conselho Federal de Medicina (CFM) / AMB

Annual

Official Examination Frequency Conducted by SBOC and AMB

Sociedade Brasileira de Oncologia Clínica (SBOC)

The TEOC (Título de Especialista em Oncologia Clínica) is the premier Brazilian clinical oncology board certification examination administered annually by SBOC and AMB. It consists of a 100-question theoretical phase testing national and international oncology guidelines and landmark clinical trials, alongside a theoretical-practical clinical case evaluation testing real-world oncologic decision-making, molecular biomarker stratification, and toxicity management.

Sample TEOC Oncologia Clínica Practice Questions

Try these sample questions to test your TEOC Oncologia Clínica exam readiness. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1A 42-year-old premenopausal woman presents with a palpable 3.2 cm mass in the upper outer quadrant of the right breast. Core needle biopsy confirms invasive ductal carcinoma, histological grade 3, estrogen receptor (ER) 0%, progesterone receptor (PR) 0%, and HER2 immunohistochemistry 0 (triple-negative breast cancer). Right axillary ultrasound-guided fine needle aspiration reveals metastatic carcinoma in one lymph node (cT2 cN1 cM0, Stage IIB). Based on the landmark KEYNOTE-522 trial and SBOC guidelines, what is the standard neoadjuvant systemic therapy regimen for this patient?

A.Dose-dense AC (doxorubicin and cyclophosphamide) followed by paclitaxel alone for 8 cycles without immunotherapy.

B.Neoadjuvant pembrolizumab combined with carboplatin and paclitaxel, followed by pembrolizumab with doxorubicin (or epirubicin) and cyclophosphamide, followed after definitive surgery by adjuvant pembrolizumab to complete 1 year.

C.Neoadjuvant carboplatin and paclitaxel followed by surgery, reserving pembrolizumab exclusively for the adjuvant setting in case of residual disease.

D.Neoadjuvant chemotherapy with docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) followed by adjuvant T-DM1.

Explanation: The KEYNOTE-522 phase III trial established that adding pembrolizumab to neoadjuvant platinum-taxane and anthracycline-cyclophosphamide chemotherapy, followed by adjuvant pembrolizumab for up to 9 cycles (completing approximately 1 year of immunotherapy), significantly improves pathological complete response (pCR) rates and event-free survival (EFS) in patients with stage II and III triple-negative breast cancer regardless of PD-L1 expression.

2A 56-year-old postmenopausal woman undergoes breast-conserving surgery and axillary lymph node dissection for a 4.5 cm invasive ductal carcinoma. Pathology confirms ER 95%, PR 80%, HER2 1+ (negative), Ki-67 35%, and 5 out of 14 lymph nodes positive for macrometastases (pT2 pN2a cM0, Stage IIIA). She completes adjuvant dose-dense AC followed by paclitaxel and adjuvant radiotherapy. According to the monarchE phase III trial, which targeted agent should be added to her adjuvant endocrine therapy?

A.Palbociclib 125 mg daily (3 weeks on, 1 week off) for 2 years

B.Abemaciclib 150 mg twice daily continuously for 2 years

C.Ribociclib 600 mg daily (3 weeks on, 1 week off) for 3 years

D.Everolimus 10 mg daily continuously for 1 year

Explanation: In the phase III monarchE trial, the addition of the continuous CDK4/6 inhibitor abemaciclib (150 mg twice daily for 2 years) to standard endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) in patients with hormone receptor-positive, HER2-negative, node-positive high-risk early breast cancer (≥4 positive nodes, or 1–3 positive nodes with grade 3, tumor ≥5 cm, or centrally confirmed Ki-67 ≥20%).

3A 38-year-old woman with a documented germline BRCA1 pathogenic mutation is diagnosed with triple-negative invasive breast cancer. She completes neoadjuvant dose-dense AC followed by carboplatin/paclitaxel and undergoes mastectomy with sentinel node biopsy. Surgical pathology reveals a 1.2 cm residual invasive carcinoma in the breast and 1 micrometastatic lymph node (non-pCR, residual cancer burden class II). According to the OlympiA trial, which adjuvant targeted therapy provides a proven overall survival benefit?

A.Olaparib 300 mg twice daily orally for 1 year

B.Talazoparib 1 mg once daily orally for 2 years

C.Capecitabine 1250 mg/m² twice daily for 6 months combined with olaparib

D.Rucaparib 600 mg twice daily orally for 1 year

Explanation: The OlympiA phase III trial demonstrated that adjuvant olaparib (300 mg orally twice daily for 1 year) significantly improved invasive disease-free survival (IDFS), distant disease-free survival (DDFS), and overall survival (OS) in patients with germline BRCA1/2-mutated, high-risk HER2-negative early breast cancer who had residual invasive disease after neoadjuvant systemic therapy or high-risk features after upfront surgery.

4A 48-year-old woman with cT2 cN1 HER2-positive (IHC 3+, ER/PR negative) invasive ductal carcinoma completes neoadjuvant chemotherapy consisting of 6 cycles of docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP). She undergoes lumpectomy and sentinel node biopsy. Histopathology shows a 1.4 cm residual invasive tumor with 2 positive lymph nodes (ypT1c ypN1a). According to the KATHERINE trial, what is the most appropriate adjuvant systemic therapy?

A.Trastuzumab plus pertuzumab to complete 1 full year of dual HER2 blockade

B.Trastuzumab emtansine (T-DM1) 3.6 mg/kg intravenously every 3 weeks for 14 cycles

C.Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg intravenously every 3 weeks for 14 cycles

D.Dose-dense AC chemotherapy followed by adjuvant trastuzumab

Explanation: In the KATHERINE phase III trial, patients with HER2-positive early breast cancer who had residual invasive disease in the breast or axilla after neoadjuvant taxane plus trastuzumab-based chemotherapy who switched to adjuvant trastuzumab emtansine (T-DM1) achieved a 50% reduction in the risk of recurrence or death (HR 0.50) compared with continuing trastuzumab alone.

5A 34-year-old premenopausal woman with high-risk luminal B breast cancer (ER 90%, PR 10%, HER2 0, grade 3, pT2 pN1a with 3 positive lymph nodes) completes adjuvant chemotherapy and radiotherapy. Her menstrual cycles resume 3 months later. Based on the joint analysis of the SOFT and TEXT trials, which endocrine therapy strategy provides the greatest reduction in breast cancer recurrence?

A.Tamoxifen 20 mg daily alone for 5 years

B.Ovarian function suppression (GnRH agonist) plus an aromatase inhibitor (exemestane) for 5 years

C.Ovarian function suppression (GnRH agonist) plus tamoxifen for 2 years followed by tamoxifen alone

D.Anastrozole 1 mg daily alone without ovarian suppression

Explanation: The combined analysis of the SOFT and TEXT trials demonstrated that in premenopausal women at high risk of recurrence (particularly those who received prior chemotherapy and remained premenopausal), ovarian function suppression (OFS) combined with the aromatase inhibitor exemestane significantly reduced recurrence rates and improved disease-free survival compared with tamoxifen alone or tamoxifen plus OFS.

6A 58-year-old postmenopausal woman with metastatic invasive ductal carcinoma to the liver and bones (ER 80%, PR 20%, HER2 IHC 1+) progresses after first-line fulvestrant plus ribociclib followed by second-line capecitabine. HER2 testing on a contemporary liver biopsy confirms HER2 IHC 1+ (HER2-low). According to the DESTINY-Breast04 phase III trial, what is the most appropriate next-line systemic therapy?

A.Trastuzumab emtansine (T-DM1)

B.Trastuzumab deruxtecan (T-DXd)

C.Sacituzumab govitecan

D.Eribulin mesylate plus lapatinib

Explanation: In the landmark DESTINY-Breast04 trial, trastuzumab deruxtecan (T-DXd) demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) compared to physician's choice chemotherapy in patients with HER2-low metastatic breast cancer (IHC 1+ or IHC 2+/ISH-) who had received one or two prior lines of chemotherapy.

7A 62-year-old woman presents with newly diagnosed de novo metastatic invasive lobular carcinoma with extensive lytic bone metastases and non-bulky retroperitoneal lymphadenopathy. Tumor biopsy shows ER 95%, PR 75%, and HER2 IHC 0. She has no visceral crisis and normal organ function. Baseline ECG reveals a normal QTc interval. Based on the MONALEESA-2 and MONALEESA-3 trials demonstrating statistically significant overall survival benefits, what is the first-line treatment of choice?

A.Letrozole plus ribociclib

B.Single-agent fulvestrant

C.Doxorubicin plus cyclophosphamide (AC chemotherapy)

D.Tamoxifen plus everolimus

Explanation: First-line CDK4/6 inhibitor therapy combined with an aromatase inhibitor (e.g., letrozole plus ribociclib) is the standard of care for postmenopausal women with HR+/HER2- metastatic breast cancer without visceral crisis, as demonstrated by substantial progression-free survival and overall survival improvements in the MONALEESA-2 trial.

8A 66-year-old woman with metastatic HR+/HER2- breast cancer experiences disease progression in the liver after 22 months of first-line anastrozole plus palbociclib. Circulating tumor DNA (ctDNA) liquid biopsy detects an ESR1 Y537S missense mutation at an allele frequency of 14.2%. PIK3CA and AKT1 are wild-type. According to the EMERALD phase III trial, which treatment is approved and guideline-recommended specifically for patients harboring activating ESR1 mutations?

A.Elacestrant 345 mg orally once daily

B.Fulvestrant combined with alpelisib

C.Tamoxifen 20 mg daily combined with everolimus

D.Capecitabine monotherapy

Explanation: The phase III EMERALD trial demonstrated that elacestrant, an oral selective estrogen receptor degrader (SERD), significantly prolonged progression-free survival compared to standard-of-care endocrine monotherapy (fulvestrant or aromatase inhibitors) in patients with ER+/HER2- metastatic breast cancer harboring ESR1 mutations who previously progressed on a CDK4/6 inhibitor.

9A 54-year-old woman with ER+/HER2- metastatic breast cancer progresses on first-line letrozole plus abemaciclib. Next-generation sequencing of a metastatic biopsy identifies a PIK3CA H1047R activating mutation. She is planned to initiate fulvestrant plus the alpha-specific PI3K inhibitor alpelisib. Which baseline clinical parameter and associated adverse event require mandatory pre-treatment screening and rigorous monitoring during alpelisib therapy?

A.Left ventricular ejection fraction and cardiotoxicity

B.Fasting plasma glucose / HbA1c and severe hyperglycemia

C.Serum amylase/lipase and acute necrotizing pancreatitis

D.Pulmonary function tests and restrictive lung disease

Explanation: Because the PI3K-alpha isoform mediates cellular insulin signaling, on-target inhibition of PI3K-alpha by alpelisib induces peripheral insulin resistance leading to high rates of severe hyperglycemia (Grade 3/4 in >35% of patients in the SOLAR-1 trial). Baseline fasting glucose and HbA1c screening followed by routine glucose monitoring and early metformin intervention are mandatory.

10A 50-year-old woman with metastatic HER2-positive (IHC 3+) breast cancer experiences progression with multiple new pulmonary metastases after 18 months of first-line docetaxel, trastuzumab, and pertuzumab. Brain MRI is negative. Based on the phase III DESTINY-Breast03 trial, which treatment should be recommended as the second-line standard of care?

A.Trastuzumab emtansine (T-DM1)

B.Trastuzumab deruxtecan (T-DXd)

C.Lapatinib plus capecitabine

D.Vinorelbine plus trastuzumab

Explanation: The randomized phase III DESTINY-Breast03 trial demonstrated that trastuzumab deruxtecan (T-DXd) achieved unprecedented improvements in both progression-free survival (HR 0.28) and overall survival compared with T-DM1 in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.

About the TEOC Oncologia Clínica Exam

The Título de Especialista em Oncologia Clínica (TEOC) is the official board certification for medical oncologists in Brazil, awarded by the Sociedade Brasileira de Oncologia Clínica (SBOC) in partnership with the Associação Médica Brasileira (AMB) and registered with the Conselho Federal de Medicina (CFM). The examination evaluates comprehensive expertise in solid tumors, hematologic malignancies, precision oncology (genomic profiling, NGS, HRD, MSI-H), modern systemic therapeutics (chemotherapy, targeted agents, ADCs, bispecifics, checkpoint inhibitors), supportive care, and oncologic emergencies. Achieving the TEOC is the definitive requirement for Brazilian oncologists to obtain their Registro de Qualificação de Especialista (RQE) in Oncologia Clínica.

Assessment

Two-day virtual examination administered by the Sociedade Brasileira de Oncologia Clínica (SBOC) and AMB. Day 1 features the Prova Teórica (100 four-option MCQs on clinical oncology, precision oncology, pharmacology, and supportive care). Day 2 features the Prova Teórico-Prática (8 clinical cases assessing diagnostic algorithms, biomarker interpretation, systemic treatment sequencing, and toxicity management).

Time Limit

2-day online examination (Prova Teórica + Prova Teórico-Prática)

Passing Score

Final composite score of at least 70 points (with a minimum eliminatory threshold of 60 points on the Prova Teórica)

Exam Fee

Set each year in the official Edital; consult the current edital for the registration fee and any member discount. (Sociedade Brasileira de Oncologia Clínica (SBOC) — Associação Médica Brasileira (AMB))

TEOC Oncologia Clínica Exam Content Outline

20%

Câncer de Mama

Molecular subtypes (Luminal A/B, HER2-enriched, Triple-Negative), genomic risk assays (Oncotype DX, MammaPrint), neoadjuvant/adjuvant chemotherapy, HER2-targeted therapy (trastuzumab, pertuzumab, T-DM1, T-DXd), endocrine therapy and CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib), PARP inhibitors in germline BRCA (olaparib), and metastatic treatment algorithms.

18%

Oncologia Torácica

Non-small cell lung cancer (NSCLC) molecular profiling (EGFR, ALK, ROS1, BRAF, KRAS G12C, MET exon 14, RET, HER2, PD-L1), targeted TKIs, perioperative chemo-immunotherapy, unresectable stage III consolidation durvalumab (PACIFIC), and extensive-stage small cell lung cancer (SCLC) chemo-IO.

18%

Tumores Gastrointestinais

Colorectal cancer (adjuvant fluoropyrimidine/oxaliplatin, RAS/BRAF/MSI/HER2 biomarkers, anti-EGFR vs anti-VEGF biologics, first-line pembrolizumab in MSI-H); Gastric and GEJ adenocarcinoma (HER2, Claudin 18.2, PD-L1 CPS, FLOT regimen); Hepatocellular carcinoma (atezo+bev, durva+treme); and Pancreatic adenocarcinoma (FOLFIRINOX, Gem-nab-paclitaxel).

14%

Tumores Geniturinários

Prostate cancer (localized risk groups, mHSPC doublet/triplet therapy with ARPIs/docetaxel, mCRPC sequencing, PARP inhibitors in HRR mutations, Lu-177-PSMA-617); Renal cell carcinoma (clear cell vs non-clear cell, IMDC risk scores, IO-TKI and dual IO combinations); and Urothelial carcinoma (EV+pembrolizumab, adjuvant nivolumab, FGFR inhibitors).

12%

Ginecologia Oncológica e Melanoma

Epithelial ovarian cancer (platinum sensitivity, BRCA1/2 and HRD testing, PARP inhibitor maintenance SOLO-1/PRIMA/PAOLA-1); Cervical cancer (pembrolizumab + chemo + bevacizumab KEYNOTE-826); Endometrial cancer (molecular classification POLE/dMMR/p53abn, chemo-IO); and Cutaneous melanoma (BRAF V600 targeted therapy dabrafenib+trametinib, checkpoint combinations ipi+nivo, rela+nivo).

10%

Biologia Tumoral, Medicina de Precisão e Hematologia

DNA repair pathways (homologous recombination repair, mismatch repair), next-generation sequencing (NGS), circulating tumor DNA (ctDNA liquid biopsy), tumor-agnostic therapies (TRK, RET, BRAF, MSI-H, TMB-H); and Hematologic malignancies for medical oncologists (Hodgkin lymphoma, DLBCL, follicular lymphoma, Multiple Myeloma).

Imunoterapia, Toxicidades, Emergências e Cuidados de Suporte

Immune checkpoint inhibitor mechanisms and irAEs grading/management; febrile neutropenia ASCO/IDSA MASCC score; hypercalcemia of malignancy; malignant spinal cord compression; superior vena cava syndrome; tumor lysis syndrome (Cairo-Bishop); and MASCC/ESMO antiemetic prophylaxis.

How to Pass the TEOC Oncologia Clínica Exam

What You Need to Know

Passing score: Final composite score of at least 70 points (with a minimum eliminatory threshold of 60 points on the Prova Teórica)
Assessment: Two-day virtual examination administered by the Sociedade Brasileira de Oncologia Clínica (SBOC) and AMB. Day 1 features the Prova Teórica (100 four-option MCQs on clinical oncology, precision oncology, pharmacology, and supportive care). Day 2 features the Prova Teórico-Prática (8 clinical cases assessing diagnostic algorithms, biomarker interpretation, systemic treatment sequencing, and toxicity management).
Time limit: 2-day online examination (Prova Teórica + Prova Teórico-Prática)
Exam fee: Set each year in the official Edital; consult the current edital for the registration fee and any member discount.

Keys to Passing

Work through all 100 available questions
Review every answer and explanation
Track weak areas and revisit them
Use our AI tutor for tough concepts

TEOC Oncologia Clínica Study Tips from Top Performers

1Master Landmark Phase III Clinical Trials: Memorize pivotal trial names, hazard ratios, and clinical endpoints across major tumor types (e.g., KEYNOTE-522, monarchE, DESTINY-Breast03/04, ADAURA, FLAURA, CheckMate-816, KEYNOTE-177, ToGA, IMbrave150, EV-302, SOLO-1, CheckMate-067).

2Internalize Biomarker Testing & Precision Oncology: Know exact cutoffs and clinical actions for EGFR mutations (exon 19 del, L858R, T790M, exon 20 ins), ALK/ROS1/RET/NTRK fusions, KRAS G12C, BRAF V600E/K, HER2 IHC/ISH, Claudin 18.2 IHC, and PD-L1 TPS vs CPS scoring.

3Understand Systemic Regimen Sequences & Pharmacology: Master modern chemotherapy backbones (FOLFOX, FOLFIRINOX, FLOT, AC-T, Gem-Cis), antibody-drug conjugate (ADC) payloads and mechanisms (T-DXd, T-DM1, Sacituzumab Govitecan, Enfortumab Vedotin), and CDK4/6, PARP, and FGFR inhibitors.

4Manage Immune-Related Adverse Events (irAEs): Memorize CTCAE grading and treatment algorithms for checkpoint inhibitor toxicities: high-dose corticosteroids (1-2 mg/kg/day methylprednisolone/prednisone), steroid-refractory colitis (infliximab or vedolizumab), hypophysitis, myocarditis, and pneumonitis.

5Calculate Staging and Risk Scores: Be fluent with AJCC/UICC TNM 8th Edition staging criteria, IMDC risk score in metastatic RCC, Cairo-Bishop criteria for tumor lysis syndrome, and the MASCC score (>21 vs <21) for febrile neutropenia risk stratification.

6Practice Timed Comprehensive MCQ Blocks: Regularly solve multi-step clinical vignettes to reinforce rapid diagnostic deduction, molecular biomarker integration, and guideline-adherent regimen selection.

Frequently Asked Questions

What is the TEOC and why is it essential for medical oncologists in Brazil?

The Título de Especialista em Oncologia Clínica (TEOC) is the official medical specialist certification awarded by the Sociedade Brasileira de Oncologia Clínica (SBOC) in partnership with the Associação Médica Brasileira (AMB). Passing the TEOC examination enables physicians to register their specialized qualification (Registro de Qualificação de Especialista - RQE) in Clinical Oncology with the Regional Medical Councils (CRMs) and Federal Council of Medicine (CFM), which is legally required to formally practice and advertise as a medical oncologist in Brazil.

What are the eligibility requirements to sit for the TEOC examination?

Candidates must be fully licensed physicians registered with a Regional Medical Council (CRM) in Brazil and meet one of the qualifying pathways: (1) Completion of an accredited Medical Residency Program (CNRM/MEC) in Clinical Oncology (Oncologia Clínica); (2) Completion of an SBOC-recognized Specialization Program; or (3) Proven clinical practice in Clinical Oncology for at least double the duration of official residency (6 years), documented institutional experience, and required academic/scientific curricular points as specified in the annual SBOC notice (Edital).

How is the TEOC examination structured across its stages?

The examination is conducted virtually over two consecutive days: (1) Prova Teórica (Theoretical Exam), consisting of 100 multiple-choice questions with 4 alternatives covering solid tumors, hematology, precision oncology, pharmacology, and supportive care; and (2) Prova Teórico-Prática (Theoretical-Practical Exam), comprising 8 structured clinical cases testing biomarker interpretation, treatment sequencing, multidisciplinary management, and toxicity handling.

What is the passing score and grading criteria for the TEOC?

Candidates must achieve a minimum composite final score of 70 points out of 100 across both stages. A minimum eliminatory cutoff of 60 points on the Prova Teórica is required to qualify for evaluation of the Prova Teórico-Prática, and candidates cannot score zero on any section.

Which clinical guidelines and evidence sources are tested on the TEOC?

The examination tests the official Diretrizes da Sociedade Brasileira de Oncologia Clínica (SBOC), complemented by landmark international phase III clinical trial evidence and consensus guidelines from ASCO, ESMO, and NCCN. Key focus areas include biomarker-driven precision oncology (NGS, HRD, MSI-H, PD-L1), targeted therapies, antibody-drug conjugates (ADCs), immune checkpoint inhibitors, and supportive care guidelines (MASCC/ESMO).

Why is this OpenExamPrep practice bank presented in English?

This practice bank is an English-language MCQ study adaptation designed to support Brazilian oncologists revising key international clinical trial acronyms and evidence, as well as international fellows. All official Brazilian clinical oncology terminology, SBOC guideline criteria, and regulatory considerations are preserved inline.